Most Favored Patient Act of 2026

This bill would require the Center for Medicare and Medicaid Innovation to run a Most Favored Nations Pricing Model for 5 years, beginning January 1, 2029. Under the model, drug manufacturers without a qualifying agreement with the federal government would have to give Medicaid, Medicare Part D, and Medicare Part B patients and their providers access to a set price for certain drugs. That price is the second-lowest net price paid for the drug among eight countries: Canada, Denmark, France, Germany, Italy, Japan, Switzerland, and the United Kingdom, adjusted for purchasing power. Manufacturers would also have to report pricing information to the government. Manufacturers could avoid the model by signing an agreement by December 31, 2028 that offers the same pricing and commits to increasing U.S. manufacturing.

Full text and official record on Congress.gov

Sponsors

• Daniel Meuser Republican sponsor
• 0 cosponsors